Comparative Efficacy of Peptides vs. Anabolic Steroids

Two Different Kinds of Drug

Anabolic-androgenic steroids (AAS) and performance peptides are often compared as if they were rival products for the same job. On efficacy they aren't close. Steroids bind the androgen receptor directly in muscle, and randomized human trials have measured what that does. Most performance peptides work upstream by raising the body's own growth hormone, or act on repair pathways that have mainly been studied in animals.

This page sticks to results. It covers what each class has been shown to do for muscle and strength, what's known about injury recovery and fat loss, and how strong the evidence is behind each claim. Our comparison of peptides and traditional anabolic steroids goes deeper on mechanisms and side effects. For risk and US legal status, see the comparative analysis of peptides and traditional anabolics.

Muscle and Strength: Steroids Have the Trials

The best-known trial is a 1996 study in the New England Journal of Medicine. Bhasin and colleagues randomly assigned 43 healthy men to weekly injections of 600 mg testosterone enanthate or placebo for 10 weeks. Two of the four groups also did supervised weight training three times a week. The men who got testosterone and trained gained about 6.1 kg of fat-free mass. Their bench press rose by about 22 kg and their squat by about 38 kg. Even without training, the testosterone group grew larger arm and thigh muscles than the placebo group.

A 2001 trial by the same group showed the effect rises with dose. In 61 young men whose own testosterone had been suppressed, 20 weeks at 125 mg a week added about 3.4 kg of fat-free mass, while 600 mg a week added about 7.9 kg. Leg press strength and thigh muscle volume tracked testosterone levels too. Both trials used pharmaceutical testosterone under medical monitoring.

Peptides have nothing comparable. As of October 2026, no published trial has measured muscle or strength in healthy adults who train while using ipamorelin or CJC-1295. What exists are hormone studies. In 2006 trials in healthy adults, a single injection of CJC-1295 raised growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9-11 days. Nobody measured muscle.

The closest outcome data come from two relatives of these peptides. MK-677 is a non-peptide pill that acts on the same ghrelin receptor as ipamorelin. In a two-year randomized trial in 65 healthy adults aged 60 to 81, 25 mg daily raised fat-free mass by about 1.1 kg while the placebo group lost about 0.5 kg. Strength and function didn't change, although the authors note the study was too small to test them properly.

Growth hormone itself has been tested in fit young adults. A 2008 systematic review of 27 study samples found that injected growth hormone added about 2.1 kg of lean body mass. Strength and exercise capacity didn't seem to improve, and soft-tissue swelling was more common. If the hormone itself didn't make fit young people stronger, there's little reason to expect more from compounds that raise the body's own release.

IGF-1 LR3, the other peptide sold for muscle growth, has no published human data; we rate its evidence as preliminary.

On forums, users of GH secretagogues mostly describe better sleep and recovery rather than visible changes in muscle. Those reports are unverified, but they fit the trial data, which point to small effects on muscle at most.

Injury Recovery: High Interest, Thin Evidence

Repair is where peptides are said to beat steroids. The evidence for that claim is weaker than its popularity suggests.

We found no controlled trial in lifters showing that steroids speed tendon or ligament healing. There is a warning signal instead. In a 2015 cross-sectional study of 142 experienced male bodybuilders, 22% of long-term steroid users reported at least one tendon rupture, compared with 6% of nonusers. Upper-body ruptures occurred only in the steroid group. The histories were self-reported and the design can't prove that steroids caused the ruptures; heavier training loads could explain part of it.

BPC-157 is the peptide lifters mention most for injuries. A 2025 systematic review in HSS Journal found 36 eligible studies of its musculoskeletal effects, and 35 of them were preclinical. In those animal studies, BPC-157 improved healing of injured tendons and ligaments, as well as muscle and bone, apparently through growth-factor signaling and new blood vessel growth (angiogenesis). The single human study was a retrospective series: 7 of 12 people with chronic knee pain reported relief lasting more than six months after an injection into the joint, with no control group.

The review found no clinical safety data. A 2025 pilot study infused up to 20 mg of BPC-157 into two adults and reported no side effects, which is far too small to rule out uncommon ones. We rate BPC-157's evidence as emerging: consistent in rodents, untested in controlled human trials.

TB-500 is often sold as thymosin beta-4, but it's a seven-amino-acid fragment (LKKTETQ) of that much larger protein. Human trials of full thymosin beta-4 don't show what the fragment does. As of October 2026, FDA says it has not identified any human exposure data for the fragment, and we rate its evidence as preliminary.

Users report mixed results with both peptides, often taken together. Some describe clear improvement within weeks; others notice nothing after a month or more. Gray-market product quality may explain part of that gap. So may placebo effects, and the fact that many tendon problems improve with time and rest anyway.

Fat Loss

Steroids lower body fat in trials, though that isn't why most people take them. In the 2001 dose-response trial, fat mass fell as testosterone levels rose.

Among growth hormone peptides, the best human data belong to tesamorelin, a prescription medicine that mimics growth hormone-releasing hormone (GHRH). In a 2007 trial of 412 people with HIV and excess abdominal fat, 2 mg daily for 26 weeks cut visceral fat by 15.2%, while it rose 5.0% on placebo. It's approved only for that condition, so the result says little about lean lifters. MK-677 had no effect on visceral fat or total fat in its two-year trial, and it raised fasting glucose while lowering insulin sensitivity.

The peptide drugs with the largest effects on fat aren't performance compounds at all. In the STEP 1 trial in adults with obesity, weekly semaglutide 2.4 mg, a prescription GLP-1 medicine, cut body weight by 14.9% at 68 weeks, compared with 2.4% on placebo. Our fat-loss comparison looks at how that class compares with other options.

Side-by-Side

For Tested Athletes

The efficacy gap doesn't change the sport rules. As of October 2026, WADA's 2026 Prohibited List bans anabolic agents under S1 as non-Specified substances. BPC-157 falls under S0, the non-approved substances class. TB-500 and IGF-1 analogues such as IGF-1 LR3 sit in S2.3. S2.2.4 covers the GHRH analogues CJC-1295 and tesamorelin. It also covers the GH secretagogues ipamorelin and MK-677 along with GHRP-2 and GHRP-6. All of these are prohibited at all times. The legal status of peptides hub covers the wider US rules.

What We Still Don't Know

No study has compared a peptide with a steroid head to head. Every comparison on this page sets randomized human trials of steroids against animal studies and user reports for peptides, plus a few hormone measurements in people.

As of October 2026, no controlled human trial of BPC-157 for injury healing has published results. One registered trial is a randomized, placebo-controlled pilot at the University of Arkansas in people recovering from rotator cuff surgery. Its record describes daily subcutaneous injections of BPC-157 or placebo for 90 days and lists it as not yet recruiting, with a planned start in January 2027.

Whether GH secretagogues do anything measurable for trained lifters beyond raising hormone levels hasn't been tested. Neither has the BPC-157 and TB-500 combination that many users take for injuries.